Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
PaperCitations, authors & open-access status
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 222 citations, 2017 year and green oa status.
222
Citations
2017
Year
green
OA Status